After 20 years on the run, most-wanted fugitive Richard Graydon, also known as Fischer, was arrested July 16 aboard his 56-foot sailing vessel The Silver Lining on the East River in New York. US Marshals and the US Coast Guard intercepted the vessel and took him into custody without incident.

Graydon had built a credible biotech career under aliases. In 2017 he self-published a book on cancer genetics, presenting himself as an oncologist and former chief medical officer. In October 2022, Seattle-based Atossa Therapeutics hired him as interim chief medical officer, citing his CAR-T cell therapy experience. CEO Steven Quay welcomed his “deep experience.” In March, Immix announced Graydon as a board-certified hematologist-oncologist with over 20 years in clinical development at Merck & Co. and Johnson & Johnson, claiming he led applications for seven approved drugs including Darzalex, Carvykti, Keytruda, and Imbruvica. His listed credentials—MD and PhD from Stanford University, training at Harvard’s Massachusetts General Hospital—could not be verified.

Immix terminated Graydon after his arrest. In an SEC filing, the company stated his short tenure meant no material effect on the business.